Adma Biologics Inc (NASDAQ:ADMA) currently has a daily average trading volume of 3.62M but it saw 1456923 shares traded in last market. With a market cap of 4.85B USD, the company’s current market price of $20.33 came falling about -0.64 while comparing to the previous closing price of $20.46. In past 52 weeks, the stock remained buoying in the range of price level as high as $25.67 and as low as $9.81.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Raymond James which resumed the stock as “Strong Buy” in its note to investors issued on July 19, 2023, recommending a price target of $5 for it. Raymond James issued its recommendations for the stock as it upgraded the price target for the stock is $5.
Over the week, ADMA’s stock price is moving 4.20% up while it is -14.26% when we observe its performance for the past one month. Year-to-date it is 18.54% up and over the past year, the stock is showing an upside performance of 112.88%.
The company is expected to be releasing its next quarterly report in July, for which analysts forecasted an EPS of 0.14 while estimate for next year EPS is 0.61. In next quarter, company is expected to be making quarterly sales of $133.15M as analysts are expecting the sales for current fiscal year at $514.47M and seeing the company making $651.48M in sales next year. Moreover, analysts are in estimates of $124.25M for current-quarter revenue.
Currently, Adma Biologics Inc’s total number of outstanding shares is 238.53M with 2.58% of that held by the insiders while 88.43% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 45.52% and return on equity (ROE) at 78.45%. It has a price to earnings ratio (P/E ratio) of 24.08 while having a 20.67 of forward P/E ratio. Stock’s beta reads 0.47. Stock has a price to book (P/B) ratio of 12.99 while price to sale or P/S ratio amounts to 10.57. Its return on asset (ROA) is 48.01% on average.
